Inozyme Pharma, Inc. Announces Proposed Offering of Common Stock
27 Julio 2023 - 3:33PM
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease
biopharmaceutical company developing novel therapeutics for the
treatment of pathologic mineralization and intimal proliferation,
today announced that it is commencing an underwritten public
offering of $60,000,000 of shares of its common stock. In addition,
Inozyme intends to grant the underwriters an option for a period of
30 days to purchase up to an additional 15% of the shares of its
common stock offered in the offering. The offering is subject to
market and other conditions, and there can be no assurance as to
whether or when the offering may be completed or as to the actual
size or terms of the offering. All of the shares of common stock
are to be offered by Inozyme.
BofA Securities, TD Cowen and Piper Sandler are acting as joint
book-running managers for the offering.
A shelf registration statement on Form S-3 (File No. 333-258702)
relating to the shares of common stock to be offered in the public
offering was filed with the Securities and Exchange Commission (the
“SEC”) on August 11, 2021, and declared effective on August 23,
2021. The offering will be made only by means of a prospectus
supplement and accompanying prospectus that form a part of the
registration statement. A preliminary prospectus supplement related
to the offering will be filed with the SEC and will be available on
the SEC’s website at www.sec.gov. Copies of the preliminary
prospectus supplement and accompanying prospectus relating to the
offering may also be obtained by contacting: BofA Securities,
NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001,
Attn: Prospectus Department, or by email at:
dg.prospectus_requests@bofa.com; TD Cowen, 599 Lexington Avenue,
New York, NY 10022, or by email at Prospectus_ECM@cowen.com or by
telephone at (833) 297-2926; or Piper Sandler, Attention:
Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis,
Minnesota 55402, or by telephone at (800) 747-3924, or by email at
prospectus@psc.com.
This press release does not constitute an offer to sell, or a
solicitation of an offer to buy these securities, nor shall there
be any sale of, these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Inozyme Pharma, Inc.
Inozyme Pharma, Inc. is a clinical-stage rare disease
biopharmaceutical company developing novel therapeutics for the
treatment of diseases impacting the vasculature, soft tissue and
skeleton. Inozyme is developing INZ-701, an enzyme replacement
therapy, to address pathologic mineralization and intimal
proliferation which can drive morbidity and mortality in these
severe diseases. INZ-701 is currently in clinical trials for the
treatment of ENPP1 Deficiency and ABCC6 Deficiency.
Cautionary Note Regarding
Forward-Looking Statements
Statements in this press release about future
expectations, plans, and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
“forward-looking statements” within the meaning of The Private
Securities Litigation Reform Act of 1995. These statements include,
but are not limited to, statements regarding the proposed public
offering, including the completion of the public offering on the
anticipated terms, or at all. The words “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,”
“would” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words.
Inozyme may not actually achieve the plans,
intentions or expectations disclosed in its forward-looking
statements, and you should not place undue reliance on its
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
the forward-looking statements Inozyme makes as a result of various
risks and uncertainties, including but not limited to market and
other financial conditions, satisfaction of customary closing
conditions related to the proposed public offering, whether Inozyme
will be able to conduct, complete and receive results from clinical
trials for its product candidates on its expected timelines, or at
all, whether its cash resources will be sufficient to fund its
foreseeable and unforeseeable operating expenses and capital
expenditure requirements on its expected timeline and other
important factors discussed in the “Risk Factors” sections
contained in its annual report on file with the SEC. The
forward-looking statements included in this press release represent
Inozyme’s views as of the date hereof and should not be relied upon
as representing its views as of any date subsequent to the date
hereof. Inozyme anticipates that subsequent events and developments
will cause its views to change. However, while Inozyme may elect to
update these forward-looking statements at some point in the
future, it specifically disclaims any obligation to do so.
Contacts
Investors:Inozyme PharmaStefan Riley, Director of IR and
Corporate Communications(857) 330-8871stefan.riley@inozyme.com
Media: SmithSolve Matt
Pera973-886-9150matt.pera@smithsolve.com
Inozyme Pharma (NASDAQ:INZY)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Inozyme Pharma (NASDAQ:INZY)
Gráfica de Acción Histórica
De May 2023 a May 2024